Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Chief Medical Officer | February 20, 2026 | February 24, 2026 |
| Lyell Immunopharma, Inc.LYEL · Entity 5757 | Chief Medical Officer | February 24, 2023 | February 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,523 |
Ending reported balance
After 2026-02-24 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Grant · Acquired 55,000 · Balance 69,589 F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Row 2 · 2026-02-24 · Sale · Disposed 1,066 · Balance 68,523 F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. |
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 247,500 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Grant · Acquired 247,500 · Balance 247,500 F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.
F2: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.
F3: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Lyell Immunopharma, Inc.
Report date February 24, 2023 · Filed February 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2033-02-23 | Direct | 700,000 |
Reported balance
After 2023-02-24 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-24 · Grant · Acquired 700,000 · Balance 700,000 F2: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. |
| Common StockSEC Table I · non-derivative | Direct | 4,049 |
Reported balance
Holding disclosure · report date 2023-02-24 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,049 F1: Includes 2,495 shares acquired on May 18, 2022 and 1,554 shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 2,495 shares acquired on May 18, 2022 and 1,554 shares acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F2: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 24, 2026 Filed Feb 24, 2026 20:53 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | SaleCommon Stock | 1,066 | $1.96 | $2,089.36 |
DisclosureSEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · nonDerivative · entry 2 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,523 F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:53 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 247,500 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · derivative · entry 3 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 247,500 Underlying: Common Stock · 247,500 shares Expires 2036-02-19 F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 20:53 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · nonDerivative · entry 1 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,589 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:20 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 66,137 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001917391-25-000003 · wk-form4_1740187228.xml · derivative · entry 2 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,137 Underlying: Common Stock · 66,137 shares Expires 2035-02-19 F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 20:20 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantCommon Stock | 14,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001917391-25-000003 · wk-form4_1740187228.xml · nonDerivative · entry 1 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,589 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 16:07 UTC | Caribou Biosciences, Inc. CRBU · Entity 6445 | GrantOption to purchase Common Stock · Derivative | 300,000 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001917391-24-000009 · wk-form4_1724184417.xml · derivative · entry 1 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2034-08-18 F1 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, August 19, 2025, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 18:19 UTC | Lyell Immunopharma, Inc. LYEL · Entity 5757 | GrantOption (right to buy) · Derivative | 700,000 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001209191-23-013848 · doc4.xml · derivative · entry 2 Albertson Tina M. · CIK 0001917391 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700,000 Underlying: Common Stock · 700,000 shares Expires 2033-02-23 F2 · derivative.exercise_date: 12.5% of the option shares shall vest on August 9, 2023, with the remaining option shares to vest in equal monthly installments over the following forty-two months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.